Celine Devroye
Bordeaux, 33000, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Oxytocin seals the blood-brain barrier, improving 22q11.2 deletion syndrome trajectories.
Journal: Brain : a journal of neurology
Published: November 10, 2023
Dysbindin-1A modulation of astrocytic dopamine and basal ganglia dependent behaviors relevant to schizophrenia.
Journal: Molecular psychiatry
Published: January 14, 2022
Correction: Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study.
Journal: Molecular psychiatry
Published: June 23, 2021
Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study.
Journal: Molecular psychiatry
Published: September 14, 2020
Serotonin2B receptor blockade in the rat dorsal raphe nucleus suppresses cocaine-induced hyperlocomotion through an opposite control of mesocortical and mesoaccumbens dopamine pathways.
Journal: Neuropharmacology
Published: July 09, 2020
Dopamine-mediated immunomodulation affects choroid plexus function.
Journal: Brain, behavior, and immunity
Published: January 30, 2019
The epistatic interaction between the dopamine D3 receptor and dysbindin-1 modulates higher-order cognitive functions in mice and humans.
Journal: Molecular psychiatry
Published: May 18, 2018
The central serotonin2B receptor as a new pharmacological target for the treatment of dopamine-related neuropsychiatric disorders: Rationale and current status of research.
Journal: Pharmacology & therapeutics
Published: August 01, 2017
Opposite control of mesocortical and mesoaccumbal dopamine pathways by serotonin2B receptor blockade: Involvement of medial prefrontal cortex serotonin1A receptors.
Journal: Neuropharmacology
Published: February 06, 2017
Differential control of dopamine ascending pathways by serotonin2B receptor antagonists: New opportunities for the treatment of schizophrenia.
Journal: Neuropharmacology
Published: February 17, 2016
Central serotonin(2B) receptor blockade inhibits cocaine-induced hyperlocomotion independently of changes of subcortical dopamine outflow.
Journal: Neuropharmacology
Published: March 25, 2015
Last Updated: 09/26/2026